Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025

Jasper Therapeutics (JSPR) announced that four abstracts on briquilimab, its c-Kit targeting antibody, have been accepted for the EAACI Congress 2025, with presentations including initial Phase 1b/2a data on cold urticaria and symptomatic dermographism, and updates on chronic spontaneous urticaria and asthma efficacy; however, the company cautioned that these are forward-looking statements subject to clinical development risks and uncertainties.

Analysis

Jasper Therapeutics (JSPR) is poised to present four abstracts on its lead c-Kit targeting antibody, briquilimab, at the EAACI Congress 2025 from June 13-16, a development viewed with mildly positive sentiment and a cautious tone. Key updates will include initial clinical data from the SPOTLIGHT Phase 1b/2a study focusing on cold urticaria and symptomatic dermographism, as well as efficacy data for chronic spontaneous urticaria and asthma, where briquilimab has previously demonstrated rapid and clinically meaningful disease control. Despite these promising advancements and the potential for increased visibility, Jasper prudently underscores the substantial risks and uncertainties inherent in clinical development, emphasizing the forward-looking nature of its statements. Recent institutional activity indicates a greater number of funds decreasing positions (62) than increasing (29) in the most recent quarter; this includes complete divestitures by entities such as BRAIDWELL LP and SAMSARA BIOCAPITAL in Q1 2025, although T. ROWE PRICE notably increased its holdings by over 755%. Insider trading activity over the past six months has been minimal, comprising a single sale by the Chief Operating Officer of 900 shares, valued at approximately $19,899. Analyst sentiment remains constructive, with three firms (RBC Capital, BTIG, BMO Capital) issuing buy or outperform ratings between December 2024 and January 2025, contributing to a median price target of $55.5 from two analysts.

Key Decisions for Investors

• Investors should closely monitor the initial clinical data from the SPOTLIGHT Phase 1b/2a study to be presented at the EAACI Congress in mid-June 2025, as these results represent a significant near-term catalyst for Jasper Therapeutics.
• Carefully evaluate the divergent institutional sentiment, characterized by significant fund exits alongside substantial new investments, in conjunction with the inherent risks of a clinical-stage biotechnology company before adjusting positions in JSPR.
• Consider the existing positive analyst ratings and price targets as potential upside indicators, but weigh these against the company's explicit cautionary statements regarding forward-looking information and the recent, albeit minor, insider selling activity.